The factor XIII Val34Leu polymorphism decreases whole blood clot mass at high fibrinogen concentrations

Sravya Kattula, Zsuzsa Bagoly, Noémi Klára Tóth, László Muszbek, and Alisa S. Wolberg

SUPPLEMENTAL FIGURES



Supplemental figure 1. FXIII is not present in peak 1 fibrinogen preparation. Fibrinogen peak 1 was analyzed to identify potential contaminating FXIII antigen and activity by western blot detection of (A) FXIII-A subunit and (B) fibrin crosslinking, respectively. Lanes are: (1) peak 1 fibrinogen (unclotted negative control), (2) peak 1 fibrinogen + thrombin + EDTA (uncrosslinked negative control), (3) peak 1 fibrinogen + thrombin + calcium, and (4) unfractionated fibrinogen + thrombin + calcium (crosslinked positive control). HMW, high molecular weight fibrin species.



Supplemental figure 2. Purified FXIII$^{Val/Val}$ and FXIII$^{Leu/Leu}$ zymogens. FXIII$^{Val/Val}$ and FXIII$^{Leu/Leu}$ zymogens (10 µg) were purified from human plasma, subjected to non-reducing SDS-PAGE (7.5% gel) to separate the FXIII-A and -B subunits, and stained with Coomassie Brilliant Blue.